Naivety leads me to having both. Approximate equal $. Assuming that most people that own MDGL knows about VKTX and vice versa, there must be some reasons for valuation difference. Perhaps timing, maturity of trials, disease severity/stages and IP runway. I choose not to argue with market perception wrt mdgl/vktx. Also probably a bad assumption to assign the same percentage premium to different companies, ie assume acquiring company(s) are stupid.
PS. back to question, who are the likeliest companies to want these molecules.
News 
Market Data 
Discover 
